» Articles » PMID: 39627265

Assessment of Molecular Modulation by Multifrequency Electromagnetic Pulses to Preferably Eradicate Tumorigenic Cells

Overview
Journal Sci Rep
Specialty Science
Date 2024 Dec 3
PMID 39627265
Authors
Affiliations
Soon will be listed here.
Abstract

Physics methods of cancer therapy are extensively used in clinical practice, but they are invasive and often confront undesired side effects. A fully new equipment that allows sustained emission of intense and time-controlled non-ionizing multifrequency electromagnetic pulse (MEMP), has been applied to eukaryotic cells in culture. The equipment discriminates the overall electronegative charge of the cell cultures, and its subsequent proportional emission may thereby become higher and lethal to cancer cells of generally high metabolic activity. In contrast, low tumorigenic cells would be much less affected. We tested the specificity and efficacy of the equipment against a collection of (i) highly tumorigenic cells of human (glioblastoma, cervical carcinoma, and skin) and mouse (colon adenocarcinoma) origin; (ii) cell lines of much lower tumorigenicity (non-human primate kidney and mouse fibroblasts), and (iii) primary porcine macrophages lacking tumorigenicity. Time and intensity control of the MEMP allowed progressive decay of viability fairly correlating to cell tumorigenicity, which was provoked by a proportional alteration of the cytoplasmic membrane permeability, cell cycle arrest at G2, and general collapse of the actin cytoskeleton to the perinuclear region. Correspondingly, these effects drastically inhibited the proliferative capacity of the most tumorigenic cells in clonogenic assays. Moreover, MEMP suppressed in a dose-dependent manner the tumorigenicity of retrovirally transduced luciferase expressing colon adenocarcinoma cells in xenografted immune-competent mice, as determined by tumor growth in a bioluminescence imaging system. Our results support MEMP as an anti-cancer non-invasive physical treatment of substantial specificity for tumorigenic cells with promising therapeutic potential in oncology.

References
1.
Mueller M, Peter W, Mappes M, Huelsen A, STEINBAUER H, Boukamp P . Tumor progression of skin carcinoma cells in vivo promoted by clonal selection, mutagenesis, and autocrine growth regulation by granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor. Am J Pathol. 2001; 159(4):1567-79. PMC: 1850484. DOI: 10.1016/S0002-9440(10)62541-2. View

2.
Kotulova J, Hajduch M, Dzubak P . Current Adenosinergic Therapies: What Do Cancer Cells Stand to Gain and Lose?. Int J Mol Sci. 2021; 22(22). PMC: 8617980. DOI: 10.3390/ijms222212569. View

3.
Palma C, Bigioni M, Irrissuto C, Nardelli F, Maggi C, Manzini S . Anti-tumour activity of tachykinin NK1 receptor antagonists on human glioma U373 MG xenograft. Br J Cancer. 2000; 82(2):480-7. PMC: 2363296. DOI: 10.1054/bjoc.1999.0946. View

4.
Rosen A . Mechanism of action of moderate-intensity static magnetic fields on biological systems. Cell Biochem Biophys. 2003; 39(2):163-73. DOI: 10.1385/CBB:39:2:163. View

5.
Vander Heiden M, Cantley L, Thompson C . Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science. 2009; 324(5930):1029-33. PMC: 2849637. DOI: 10.1126/science.1160809. View